Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

63 results about "Pcr cloning" patented technology

PCR cloning differs from traditional cloning in that the DNA fragment of interest, and even the vector, can be amplified by the Polymerase Chain Reaction (PCR) and ligated together, without the use of restriction enzymes. PCR cloning is a rapid method for cloning genes, and is often used for projects...

pREM: a positive selection vector system for direct PCR cloning

InactiveUS6544782B1Eliminate and greatly reduce false positive cloneSimple cloningSugar derivativesFermentationEscherichia coliBiology
The present invention describes the development of a positive selection vector based on regulatory element modulation, wherein such modulation is achieved via insertional reconstruction or destruction of a regulatory element controlling transcription, translation, DNA replication and termination. A positive selection cloning vector pREM5Tc has been developed based on insertional reconstruction of a regulatory element of a reporter gene. The vector pREM5Tc carries the tetracycline resistance reporter gene with no functional -35 region of its promoter, a regulatory element, thus resulting in no expression of the tetracycline resistance gene. Hence a host cell carrying the vector pREM5Tc is unable to produce the tetracycline resistance gene protein resulting in inhibition of its growth in presence of tetracycline. An E. coli consensus -35 region is recognized as 5'-TTGACA-3' and a primer used in polymerase chain reaction (PCR) carries at its 5' end the sequence 5'-TGTCAA-3', which is the complementary sequence of 5'-TTGACA-3'. The PCR-amplified DNA fragment is ligated to pREM5Tc thus reconstructing the functional promoter of the tetracycline resistance reporter gene. Subsequent transformation of a host cell with the recombinant vector (carrying an insert DNA) results in production of the tetracycline resistance reporter gene protein that confers resistance to tetracycline thus allowing only the recombinants to grow in presence of tetracycline. The positive selection vector pREM5Tc greatly reduces, if not eliminates, the number of exonuclease-generated false positive clones.
Owner:SYNTHEGEN SYST

High fidelity PCR cloning

The present invention describes a methodology for generating high fidelity PCR products, and also cloning of such high fidelity PCR products in a suitable vector. Generation of polymerase-induced mutant fraction of target sequences during PCR amplification is linearly proportional to the number of doublings of the target sequences. Thus the high fidelity PCR products are generated by minimizing the number of doublings of the target nucleic acid sequences during PCR amplification. Minimization of number of doublings of the target sequences is achieved by reducing the number of cycles of PCR amplification of the target sequences. The high fidelity PCR products thus obtained are then cloned into a suitable vector. As an example, a 960 bp target sequence from E. coli DNA was PCR-amplified only for 3 cycles, and it was then directly cloned into a positive selection cloning vector pRGR2Ap. The functional analysis of the inserts in all clones showed that the clones carried functionally wild-type DNA fragments, and hence the inserts most probably carry no mutation. Cloning of PCR products obtained from 3 cycles of amplification, instead of 30 cycles of amplification, theoretically achieves 10-fold reduction of mutations in the cloned fragments. The invention also contemplates cloning of a target cDNA obtained by primer extension.
Owner:SYNTHEGEN SYST

Chlamydia pneumonia antigen, method for preparing antigen, fast detection method and reagent for detecting anti-chlamydia pneumonia antibody by utilizing antigen

The invention relates to a chlamydia pneumonia genetic engineering expression artificial antigen, and a method for preparing the antigen. The method comprises the steps of: cloning and amplifying a chlamydia pneumonia MOMP (major outer membrane protein) antigen gene sequence by PCR (polymerase chain reaction), building a prokaryotic expression vector, expressing chlamydia pneumonia MOMP antigen protein by escherichia coli, and obtaining a reconstructed chlamydia pneumonia MOMP antigen with a three-dimensional structure and immunological competence by a dialysis method, a gradient dilution method and a gel chromatography renaturation inclusion body. A fast detection method for detecting the chlamydia pneumonia antigen antibody is provided. The method comprises the application of the chlamydia pneumonia antigen; and the invention provides a fast detection reagent for detecting the chlamydia pneumonia antibody. The reagent contains the chlamydia pneumonia antigen. According to the invention, the chlamydia pneumonia antigen is provided. The antigen has high specificity. The method for preparing the antigen, the method for fast measuring the chlamydia pneumonia antibody, and the reagent for fast measuring the chlamydia pneumonia antibody are provided by the invention.
Owner:李克生

Single domain antibody resisting to human nerve dynein 1 and preparation method of single domain antibody

The invention discloses a single domain antibody resisting to human nerve dynein 1 and a preparation method of the single domain antibody and belongs to the technical field of genetic engineering and antibody engineering. The preparation method comprises the steps of cloning genes of the single domain antibody resisting to the human nerve dynein 1, introducing the genes into a vector, and constructing a recombinant vector; introducing the recombinant vector into a host bacterium, and constructing a recombinant bacterium which expresses the single domain antibody resisting to the human nerve dynein 1; fermenting and culturing the recombinant bacterium, separating and purifying fermentation liquor, and obtaining the single domain antibody resisting to the human nerve dynein 1. According to the single domain antibody resisting to the human nerve dynein 1 and the preparation method of the single domain antibody, a hybridoma cell strain A6 of the monoclonal antibody antibody resisting to the human nerve dynein 1 serves as the template, and RT-PCR cloning is conducted, so that the heavy chain variable region gene (V<H>) of the antibody is obtained; the gene is introduced into the plasmid vector pET-22b (+), and the recombinant vector pET-22b(+)-V<H> is constructed; the recombinant vector is introduced into the expression strain E. coli BL21(DE3), IPTG induces expression of the single domain antibody resisting to the human nerve dynein 1, and then purification and identification are conducted.
Owner:XIAMEN UNIV

Brassica napus BnGLABRA2 promoter and preparation method and application thereof

The invention discloses a brassica napus BnGLABRA2 promoter and a preparation method and application thereof. The method comprises the following steps of: A, cloning a promoter sequence by genomic walking, namely extracting genomic DNA (Deoxyribose Nucleic Acid) by using an SDS (Sodium Dodecyl Sulfonate) cracking method, performing genomic walking, and amplifying PCR (Polymerase Chain Reaction) cloned rape twice during each genomic walking; B, performing bioinformatics analysis on the promoter sequence, namely performing homology comparison on a cloned sequence by BLASTN, wherein a promoter sequence and an upstream promoter element are obtained from a promoter core element and an upstream cis acting element by using promoter prediction software; and C, amplifying a full-length promoter and a missing promoter and constructing a pMD18-T-GP vector, namely designing and amplifying a primer of each missing segment by taking the genomic DNA as a template according to the previously obtained promoter sequence for PCR amplification. The application of the brassica napus BnGL2 genomic full-length promoter SEQ ID NO:1 to leaf epidermal hairs, seeds, root parts, entire veins and stele leaf veins is disclosed. The method has the advantages of easiness in operating, stable and reliable result. The brassica napus BnGLABRA2 promoter has biological safety and development and application values.
Owner:INST OF OIL CROPS RES CHINESE ACAD OF AGRI SCI

Heterologous expression and purification method for human RANTES protein having chemotaxis

The invention relates to heterogeny expression and purification method of a human RANTES protein with chemotaxis. A Pichia pastoris expression system with the advantages of high expression, high stability, high exudation and low cost is adopted and the protocols in molecular biology and the protein expressing and purifying technology which include cloning a human RANTES gene, building a human RANTES fusion protein expression vector and the methanol induction expressing and purifying authentication of the human RANTES fusion protein through PT-PCR, and the like are adopted for realizing the exudation expression of the human RANTES protein. In order to be convenient for the separation and purification of the human RANTES protein, a 6 multiplied by His purifying label is fused at the N end of a target protein, and moreover, an enterokinase(EK) restriction enzyme locus is added between His-tag and the RANTES protein for building the RANTES fusion protein; then the human RANTES protein with higher purity and larger yield is obtained through affinity chromatography and EK restriction enzyme locus; and the protein can be used for preparing the medicaments for curing multiple sclerosis arthritis, rheumatoid arthritis, organ transplantation rejection, cardiovascular and cerebrovascular disease, knub and HIV.
Owner:CHONGQING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products